FLT3 and acute myeloid leukemia: In AML, the likelihood of MRD after chemotherapy is substantially greater in patients harboring activating FLT3 internal tandem duplication (FLT3‐ITD) mutations than in patients with wild‐type FLT3. 6However, as FLT3‐ITD mutations do not always persist at relapse, systematic monitoring of FLT3‐ITD mutations in patients in first remission remains controversial.7